EUVIMEDEUVIMED entdecken
Crossref

Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas

Guilhem Stien, Tiphaine Obara, Mike Truong, Timothee Zaragori, Marie Blonski, Luc Taillandier, Antoine Verger iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-07 · 53 (8) · 5101-5109

DOI: 10.1007/s00259-026-07895-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 17.04.2026. Verfasst von Guilhem Stien und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, CHRU of Nancy, Nancy, France. Hauptthemen laut MEDLINE: Glioma, Positron-Emission Tomography, Mutation, Isocitrate Dehydrogenase. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Mutant IDH (mIDH) inhibitors represent a novel therapeutic approach for IDH-mutant gliomas. This study aimed to evaluate the role of amino acid PET in monitoring the response to mIDH inhibitor treatment in patients with refractory IDH-mutant gliomas. METHODS: Patients with confirmed IDH-mutant gliomas who received mIDH inhibitor treatments, ivosidenib or vorasidenib, between February 2022 and November 2024, with baseline [¹⁸F]-FDOPA scans, were included. Lesions were assessed using the RANO 2.0 and PET RANO criteria to determine measurability and, in patients with early follow-up imaging, to predict 6-month progression-free survival (PFS-6). RESULTS: Twenty-two patients were included (mean age: 42.1 ± 10.5 years; 8 women; 14 with IDH-mutant astrocytomas). Among them, 11 underwent follow-up imaging with both MRI and PET within the first 100 days of treatment. At baseline, MRI identified measurable lesions in 10 of 22 patients (45%), whereas amino acid PET identified lesions in 20 of 22 patients (91%) (p 0.05). The only discordant case showed progression on PET but stability on MRI, with confirmed clinical progression at 10 months post-treatment initiation. CONCLUSION: Amino acid PET is a valuable tool for identifying measurable lesions in patients with refractory IDH-mutant gliomas. Moreover, in this specific population, its performance for monitoring treatment with mIDH inhibitors is at least comparable to that of MRI. CLINICAL TRIAL REGISTRATION: Trial was registered at ClinicalTrials.gov (NCT07017790) and complied with the principles of the Declaration of Helsinki.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaPositron-Emission TomographyMutationIsocitrate DehydrogenaseAmino AcidsBrain NeoplasmsHumansFemaleAdultMaleMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

Amino acid PETFDOPAIDH-mutant gliomaMIDH inhibitors

Substanzen

Isocitrate DehydrogenaseAmino Acids

Autor:innen und Institutionen

  • Nuclear Medicine Department, CHRU of Nancy, Nancy, France.
  • Neuro-Oncology Department, CHRU of Nancy, Nancy, France.
  • Centre de Recherche en Automatique de Nancy CRAN, UMR 7039, Université de Lorraine, CNRS, Nancy, France.
  • Neuroimaging Department, CHRU of Nancy, Nancy, France.
  • CIC 1433, Inserm, CHRU of Nancy, Nancy, France.
  • IADI, U1254, Inserm, Université de Lorraine, Nancy, France.

ORCID-Profile: Antoine Verger

Zitieren

APA

Stien, G., Obara, T., Truong, M., Zaragori, T., Blonski, M., Taillandier, L., & Verger, A. (2026). Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 53(8), 5101-5109. https://doi.org/10.1007/s00259-026-07895-2

Vancouver

Stien G, Obara T, Truong M, Zaragori T, Blonski M, Taillandier L, et al. Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(8):5101-5109. doi:10.1007/s00259-026-07895-2

BibTeX
@article{Stien2026,
  author = {Stien, Guilhem and Obara, Tiphaine and Truong, Mike and Zaragori, Timothee and Blonski, Marie and Taillandier, Luc and Verger, Antoine},
  title = {Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {8},
  pages = {5101--5109},
  doi = {10.1007/s00259-026-07895-2}
}
Kostenlos starten →